FDA approves Yeztugo HIV prevention injection showing 96% efficacy in clinical trials, but $14,000 cost creates significant access barriers for patients.

The drug, lamivudine, appears to improve vision that’s being threatened by diabetic macular edema (DME), an eye condition in ...

The 2025 Warren Alpert Foundation Prize has been awarded to three scientists whose discoveries culminated in the development ...

The US Food and Drug Administration has approved lenacapavir (Yeztugo), the first twice-yearly injectable HIV-1 prevention ...

HIV response. Experts are suggesting a projected 24% decrease in HIV funding over the next year in the context of reductions ...

Botswana has approximately 360,000 people living with HIV, with 98% of pregnant women living with HIV receiving treatment ...

Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection: Foster City, California Friday, June 20, 2025, 1 ...

The majority of patients suffering from the three major infectious diseases (human immunodeficiency virus/acquired immunodeficiency syndrome (HIV ... mechanism of action from the existing drugs.

An inexpensive, long-approved HIV drug can improve vision in patients ... injections into the eye. The mechanism of action of lamivudine is also different from that of existing treatments, so ...

Now, a groundbreaking study from researchers at Boston Children’s Hospital and Harvard Medical School is offering a potential new path forward: using already FDA-approved migraine medications to ...